Profiles: Page 2

The latest opinion pieces by industry thought leaders

  • Norman Sussman, chief medical officer, Durect
    Image attribution tooltip
    Permission granted by Durect
    Image attribution tooltip

    Forks in the road lead one medical expert to a ‘game changing’ liver treatment

    Durect’s chief medical officer altered his retirement plans to take a leading role at the company, which is developing a treatment for severe alcohol-associated hepatitis.

    Alexandra Pecci • Jan. 3, 2023
  • Stephen Quake, head of science, Chan Zuckerberg Initiative
    Image attribution tooltip
    Permission granted by CZI
    Image attribution tooltip

    How one of the world’s most prolific inventors is guiding a plan to tackle all disease

    Steve Quake, science head at the Chan Zuckerberg Initiative, is leveraging personal experiences and a deep background in R&D to lead an ambitious 100-year plan.

    Alexandra Pecci • Dec. 15, 2022
  • Professional headshot of Mahesh Karande
    Image attribution tooltip

    Permission granted by Mahesh Karande

    Image attribution tooltip

    Chasing a ‘holy grail’ cancer gene

    Omega Therapeutics’ president and CEO Mahesh Karande on its attempts to drug the elusive c-Myc gene.

    Alexandra Pecci • Dec. 6, 2022
  • Professional headshot of Evelina Vågesjö
    Image attribution tooltip

    Permission granted by Evelina Vågesjö 

    Image attribution tooltip

    How bacteria-enabled technology for wounds could also help cancer patients

    Evelina Vågesjö, co-founder and CEO of the immunotherapy company Ilya Pharma, is working on a new modality to speed wound healing.

    Alexandra Pecci • Nov. 22, 2022
  • Professional headshot of Sana Alajmovic.
    Image attribution tooltip

    Permission granted by Sana Alajmovic

    Image attribution tooltip

    A ‘bold vision’ to prevent diabetes

    Despite hearing that there’s “no money in prevention,” the CEO of Sigrid Therapeutics is forging ahead with the company’s goal of stopping Type 2 diabetes before it starts. 

    Alexandra Pecci • Nov. 15, 2022
  • Professional headshot of Joe Landolina
    Image attribution tooltip

    Permission granted by Cresilon

    Image attribution tooltip

    This plant-based gel stops bleeding in seconds — and might have potential in drug delivery

    29-year-old biotech founder Joe Landolina is hoping to capitalize on major possibilities in the human health market through his startup Cresolin and just inked a research partnership with Walter Reed.

    Karissa Waddick • Nov. 9, 2022
  • Rami Elghandour headshot
    Image attribution tooltip
    Permission granted by Rami Elghandour
    Image attribution tooltip

    Chasing that ‘Time magazine cover potential’

    Rami Elghandour was already retired. Then CAR-T specialist Arcellx lured him back into the industry to try to change the world.

    Alexandra Pecci • Nov. 8, 2022
  • Tasuku Kitada head shot
    Image attribution tooltip
    Permission granted by Tasuku Kitada
    Image attribution tooltip

    A longtime believer in mRNA, Strand Therapeutics’ co-founder is now pushing the tech to the next level

    The company’s co-founder and head of R&D on how it’s using synthetic mRNA to create “smarter” therapies that could provide cures for cancer and more.

    Alexandra Pecci • Oct. 25, 2022
  • Wolly mammoth vintage
    Image attribution tooltip
    Stock illustration via Getty Images
    Image attribution tooltip

    How a company aimed at bringing the woolly mammoth back to life spun off a startup that could speed drug development

    Colossal Biosciences announced the creation of Form Bio — and its “operating system for science” — in September.

    Alexandra Pecci • Oct. 20, 2022
  • Amit Etkin horizontal
    Image attribution tooltip
    Permission granted by Amit Etkin
    Image attribution tooltip

    Harnessing the creative energy of California, Alto is advancing a novel approach to psychiatric meds

    After making the leap from academia to the world of biotech, CEO Dr. Amit Etkin is hoping to shift the treatment paradigm for neurological conditions.

    Alexandra Pecci • Oct. 11, 2022
  • A portrait of Jim Lang framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Jim Lang
    Image attribution tooltip

    Red Jacket: Jim Lang

    The CEO of Eversana has made his mark on the life sciences by disrupting the status quo for commercialization — and he’s got more industry-shifting changes in the works.

    PharmaVoice staff • Sept. 15, 2022
  • Header of Peyton Howell with PV100 logo
    Image attribution tooltip
    Permission granted by Peyton Howell
    Image attribution tooltip

    Red Jacket: Peyton Howell

    The chief operating and growth officer of Parexel has sold her market access company and created award-winning DE&I programs, but it’s her role as “connector” that she takes the greatest pride in.

    PharmaVoice staff • Sept. 15, 2022
  • Quita Highsmith header
    Image attribution tooltip
    Permission granted by Quita Highsmith
    Image attribution tooltip

    Red Jacket: Quita Highsmith

    The VP and chief diversity officer of Genentech is driving enterprise-wide strategies to influence how the biotech giant approaches DE&I — from clinical trials to career advancement.

    PharmaVoice staff • Sept. 15, 2022
  • Fabio Gratton header with PV100 logo
    Image attribution tooltip
    Permission granted by Fabio Gratton
    Image attribution tooltip

    Red Jacket: Fabio Gratton

    The serial entrepreneur has relied on his gift for storytelling, creativity and a bit of “magic” as he’s launched one successful niche tech company after another.

    PharmaVoice staff • Sept. 15, 2022
  • Udit Batra header with PV100 logo
    Image attribution tooltip
    Permission granted by Udit Batra
    Image attribution tooltip

    Red Jacket: Udit Batra

    A combination of logic and love — that’s how the CEO of Waters Corp. leads and how he inspires those around him to “solve the problems that matter.”

    PharmaVoice staff • Sept. 15, 2022
  • A portrait of Dr. Yvonne Greenstreet framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Yvonne Greenstreet
    Image attribution tooltip

    Disrupters: Dr. Yvonne Greenstreet

    The CEO of Alnylam — a leader in RNAi therapies — has the company at the top of its game scientifically and culturally.

    PharmaVoice staff • Sept. 6, 2022
  • A portrait of WeiQing Zhou framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by WeiQing Zhou
    Image attribution tooltip

    Entrepreneurs: WeiQing Zhou

    The COO has launched two jewels in the biotech world that complement each other while serving broader innovation goals throughout the industry. 

    Meagan Parrish • Sept. 6, 2022
  • A portrait of Vincent Keunen framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Vincent Keunen
    Image attribution tooltip

    Entrepreneurs: Vincent Keunen

    With his unique platform, the  has built a bridge between patients, physicians and researchers around the world.  

    Meagan Parrish • Sept. 6, 2022
  • A portrait of Trishna Bharadia framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Trishna Bharadia
    Image attribution tooltip

    Disrupters: Trishna Bharadia

    As a patient advocate, The Spark Global’s owner is transforming how pharma companies approach patient centricity.

    Alexandra Pecci • Sept. 6, 2022
  • A portrait of Dr. Tania Small framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Dr. Tania Small
    Image attribution tooltip

    Disrupters: Dr. Tania Small

    GSK’s medical oncology head is paving the way for patient-driven drug development and more equitable care.

    PharmaVoice staff • Sept. 6, 2022
  • A portrait of Dr. Steven Steinhubl framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Dr. Steven Steinhubl
    Image attribution tooltip

    Legacy Leaders: Dr. Steven Steinhubl

    The chief medical officer at physIQ is working at the intersection of healthcare, clinical trials and technology to deliver better, faster and more accurate treatments to patients around the globe.

    Karissa Waddick • Sept. 6, 2022
  • A portrait of Dr. Stephen Dale framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Dr. Stephen Dale
    Image attribution tooltip

    Innovators: Dr. Stephen Dale

    The CMO at Kura Oncology, a clinical-stage biopharma company, is charting a new course to deliver on the promise of precision medicine in oncology.

    PharmaVoice staff • Sept. 6, 2022
  • A portrait of Simba Gill framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Simba Gill
    Image attribution tooltip

    Disrupters: Simba Gill

    The CEO of Evelo Biosciences is going where no one else in biotech has gone before.

    Meagan Parrish • Sept. 6, 2022
  • A portrait of Shanthi Ganeshan framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Shanthi Ganeshan
    Image attribution tooltip

    Innovators: Shanthi Ganeshan

    The longtime regulatory pro has used innovative strategies to deliver emerging oncology therapies to patients from her position as head of regulatory affairs at Stemline.

    Meagan Parrish • Sept. 6, 2022
  • A portrait of Sebastian Guth framed with a banner icon that reads "PV 100"
    Image attribution tooltip
    Permission granted by Sebastian Guth
    Image attribution tooltip

    DE&I Champions: Sebastian Guth

    Bayer Pharmaceuticals’ president, Americas Region, is driving equality efforts both within the company and for patients.

    PharmaVoice staff • Sept. 6, 2022